PHOENIX, June 18, 2018 (GLOBE NEWSWIRE) -- Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” and “the Company”) was recently interviewed on Uptick Newswire’s “Stock Day” podcast. Schumacher discussed the Company’s continued financial success, the significant amount of debt the Company has converted into equity over the past 30 days, and the Company’s plans to up-list to a national exchange before the year is out.
“Although we are a QB company on the OTC Marketplace, we run the Company as if we were NASDAQ or NYSE-Amex listed. This is important, since we have expectations of moving up to a national stock exchange before the end of this year,” commented Schumacher.
Schumacher stresses that the Company has been working diligently to meet the requirements necessary to up-list PBIO to a national exchange. One such requirement is that the Company must show strong, positive stockholders equity. The Company made tremendous strides in this regard when they announced the conversion of over $13.6 million of debt into equity over the past 30 days.
Pressure BioSciences is unique in the biological field. “We’re changing a paradigm that’s existed in labs for maybe 50 years,” said Schumacher. The Company’s pressure cycling technology (“PCT”) carefully breaks cells open while minimizing damage to the important internal contents such as DNA, RNA, lipids, and proteins. Many of the other extraction methods used routinely by as many as 500,000 researchers worldwide involve breaking cells open in a more volatile and destructive ways that can actually damage the biomolecule contents or put researchers at risk. PBI’s unique PCT method is more like squeezing a sponge, and the number of squeezes and level of pressure necessary for each unique cell type can be programmed into a computer that is part of their instrument. Individualizing profiles for human, plant, animal, and other normal or cancer cell types can promote consistency in research while significantly reducing variability, so very important in scientific research.
“High pressure has not really been utilized that much in the lab up to now, mainly because until we came along, there was really no way of safely getting high pressure into the lab. We use pressures up to 6 times the pressure you would feel if you were standing at the bottom of Mariana’s Trench, with six miles of ocean on top of you. Now that is pressure!” Schumacher went on to mention that their pressure chambers can safely reach levels up to 100,000 PSI, a staggering high in the industry.
With a market cap of about $4.2 million and shares selling at just under $3, Jolly and believes that now is a great time for investors to get involved with PBI. “It’s an extremely undervalued company. It’s one of those undiscovered gems for which investors are always looking. The Company has done very well over the past 18-24 months, and we expect they will continue to do well, yet their stock price is actually down about 75% over that time. At some point, we believe they will be discovered,” said Jolly. “Until then, in our opinion, the stock price is not even close to a true reflection of the value of this company.”
To hear more about the Company’s recent debt to equity conversions, its partnership with ISS Inc., and its globally-used flagship products, please click the following link to hear the full interview on Uptick Newswire’s website.
https://upticknewswire.com/featured-interview...qb-pbio-6/
Investors Hangout is a proud sponsor of Uptick Newswire’s “Stock Day” Podcast, and encourages listeners to visit the company’s board on their website. http://www.investorshangout.com
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow immediate entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nano-emulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Contact
Pressure BioSciences, Inc. Richard T. Schumacher – President & CEO 508-230-1828
Safe Harbor Statement Statements contained in this press release regarding PBIO's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
About Uptick Newswire and the “Stock Day” Podcast Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire.
For more information about PBIO and this press release, please click on the following website link: http://www.pressurebiosciences.com
